SCHEMBL5114029

SCHEMBL5114029

N#Cc1ccc2c(c1)Sc1ccccc1N2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 4/20 0.63
NOX1 Q9Y5S8 10/20 0.59
MAPT P10636 6/20 0.59
GAA P10253 5/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
TDP1 Q9NUW8 2/20 0.59
BCHE P06276 2/20 0.59
ACHE P22303 2/20 0.59
ALOX15 P16050 2/20 0.59
CYP1A2 P05177 1/20 0.59
POLB P06746 1/20 0.59
CYP3A4 P08684 1/20 0.59
ADORA3 P0DMS8 1/20 0.59
ALOX12 P18054 1/20 0.59
MAOA P21397 1/20 0.59
CNR1 P21554 1/20 0.59
PTGS1 P23219 1/20 0.59
SLC6A2 P23975 1/20 0.59
HTR2C P28335 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30760623 0.91 SNCA (0.73) SNCANOX1MAPTGAAMEN1
SCHEMBL28486643 0.91 SNCA (0.73) SNCANOX1MAPTGAAMEN1
SCHEMBL4073961 0.90 NOX1 (0.59) SNCANOX1MAPTGAAMEN1
SCHEMBL31024122 0.90 NOX1 (0.59) SNCANOX1MAPTGAAMEN1
SCHEMBL30490473 0.88 SNCA (0.65) SNCANOX1MAPTGAAMEN1
SCHEMBL28481960 0.88 SNCA (0.65) SNCANOX1MAPTGAAMEN1
SCHEMBL11397795 0.82 L3MBTL1 (0.62) SNCANOX1MAPTGAATDP1
SCHEMBL11388958 0.82 L3MBTL1 (0.62) SNCANOX1MAPTGAAMEN1
SCHEMBL28901495 0.80 SNCA (0.54) SNCANOX1MAPTGAAMEN1
Phenothiazine SCHEMBL17006488 0.79 NOX1 (0.94) SNCANOX1MAPTGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US claimed
EP-3475277-A1 ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF Bioimics AB (SE) 2019-05-01 EP disclosed
WO-2017222466-A1 ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF BIOIMICS AB (SE) 2017-12-28 WO disclosed
US-9566284-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2017-02-14 US disclosed
US-9566284-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2017-02-14 US disclosed
US-20140235619-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO INC. (CA) 2014-08-21 US disclosed
US-20140235619-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO INC. (CA) 2014-08-21 US disclosed
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2011-10-13 US disclosed
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2011-10-13 US disclosed
US-20080318937-A1 TRICYCLIC DELTA-OPIOID MODULATORS COATS STEVEN J 2008-12-25 US disclosed
US-5503937-A MIXTURE OF A COMPOUND HAVING MORE THAN ONE EPOXY GROUP, A DIHYDRIC PHENOLIC COMPOUND AND A LATENT CATALYST COMPRISING A SALT OF AN N-HETEROCYCLIC COMPOUND AND AN ACID HAVING A STRONG NUCLEOPHILIC ANION; COATINGS/MOLDINGS; STORAGE THE DOW CHEMICAL COMPANY (US) 1996-04-02 US disclosed
CN-1118793-A Latent catalysts, cure-inhibited epxoy resin compositions and laminates prepared therefrom DOW CHEMICAL CO (US) 1996-03-20 CN disclosed
CN-1118794-A Latent Catalysts, Cure-inhibited epxoy resin compositions and laminates prepared therefrom DOW CHEMICAL CO (US) 1996-03-20 CN disclosed
EP-0553887-A2 Catalysts and epoxy resin composition containing the same THE DOW CHEMICAL COMPANY (US) 1993-08-04 EP disclosed
US-5169473-A Complex of an onium, arsenic or amine compound and boric acid; advanced polyepoxides; storage stability THE DOW CHEMICAL COMPANY (US) 1992-12-08 US disclosed
US-5134239-A Quaterinary indolizine compound THE DOW CHEMICAL COMPANY (US) 1992-07-28 US disclosed
CN-1056699-A Latent catalysts and cure-inhibited epoxy resin compositions and laminates made therefrom DOW CHEMICAL CO (US) 1991-12-04 CN disclosed
EP-0458502-A2 Latent catalysts, cure-inhibited epoxy resin compositions and laminates prepared therefrom THE DOW CHEMICAL COMPANY (US) 1991-11-27 EP disclosed
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US disclosed
EP-0328020-A2 Use of a catalyst in epoxy compositions THE DOW CHEMICAL COMPANY (US) 1989-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES TRPM7, TRPM8, TRPM6 SNCA 4055/4885NOX1 2100/4885MAPT 3464/4885
US-20080318937-A1 TRICYCLIC DELTA-OPIOID MODULATORS OPRD1, OPRK1, OPRL1 SNCA 1381/4885NOX1 4346/4885MAPT 1156/4885
US-20140235619-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES TRPM7, TRPM8, TRPM6 SNCA 4055/4885NOX1 2100/4885MAPT 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.